Bavencio (avelumab)

Avelumab has the highest risk of IRRs followed by atezolizumab and dual ICIs. This comparative study provides insight into the incidence of IRRs with ICI regimens. These results are useful in assessing which systemic therapies are responsible for IRRs, particularly when ICIs are combined with other agents.

P2, N=145, Active, not recruiting, Laura Huppert, MD, BA | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Jan 2027 | Trial primary completion date: Jun 2026 --> Jan 2027

P2, N=25, Recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

P2/3, N=956, Active, not recruiting, BicycleTx Limited | Recruiting --> Active, not recruiting

Molecular profiling leveraged IMmotion151 (A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma) trial data with whole-exome sequencing, RNA sequencing, and programmed cell death ligand 1 immunohistochemistry. Systemic standard of care treatments for mRCC, which include vascular endothelial growth factor receptor targeted therapy (VEGF-TT [sunitinib or pazopanib]), immune-oncology-VEGF (IO-VE [pembrolizumab and axitinib, pembrolizumab and lenvatinib, nivolumab and cabozantinib, or avelumab and axitinib]), and 2 IO (IO-IO [ipilimumab and nivolumab]) regimens...In this cohort study, the very favorable risk subgroup had a less immunogenic molecular profile and superior outcomes from VEGF-containing regimens (VEGF-TT and IO-VE) compared with the favorable risk group. The IO-IO combination showed significantly worse survival in this population, suggesting that VEGF inhibition remains essential for optimal outcomes.

Clinical trial outcomes with axitinib plus avelumab differ significantly by ACC subtype. Furthermore, the identified 167-gene immune-related signature predicts clinical benefit to immunotherapy-based combinations in ACC. These findings provide a framework for future biomarker-driven trial design and patient stratification strategies for this rare malignancy.

Cancer progression with the elevation of serum CA19-9 was observed during subsequent avelumab therapy, and enfortumab vedotin therapy was initiated. RARP for patients with a past history of bladder tumor presents a risk of dissemination of UC due to urine leakage. Thorough examination for UC before RARP is recommended.

The results from this multinational cohort suggest that high intratumoral infiltrations of TILs and MPs, along with low stromal FB densities, may be associated with better response to ICI-containing treatment in NPC. Further studies in larger, expanded cohorts are warranted, and prospective validation is needed.

P1/2, N=24, Active, not recruiting, Georgetown University | Trial completion date: Mar 2026 --> Apr 2027 | Trial primary completion date: Mar 2026 --> Apr 2027

P2, N=18, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027

Among them, capecitabine, S-1, bevacizumab, and avelumab were most frequently evaluated. MT, whether applied as a continuous or switching strategy, may sustain clinical benefits without compromising QoL due to severe AEs. Future studies should investigate the long-term clinical benefits of MT and its impact on resource utilization and health-related QoL.

P3, N=205, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Feb 2027 --> Aug 2026 | Trial primary completion date: Feb 2027 --> Aug 2026